收费全文 | 852958篇 |
免费 | 66032篇 |
国内免费 | 3057篇 |
耳鼻咽喉 | 14540篇 |
儿科学 | 28267篇 |
妇产科学 | 19742篇 |
基础医学 | 121522篇 |
口腔科学 | 19757篇 |
临床医学 | 89549篇 |
内科学 | 172694篇 |
皮肤病学 | 23967篇 |
神经病学 | 65932篇 |
特种医学 | 33465篇 |
外国民族医学 | 53篇 |
外科学 | 144016篇 |
综合类 | 9009篇 |
现状与发展 | 74篇 |
一般理论 | 172篇 |
预防医学 | 55902篇 |
眼科学 | 18947篇 |
药学 | 54265篇 |
1篇 | |
中国医学 | 1556篇 |
肿瘤学 | 48617篇 |
2023年 | 6257篇 |
2021年 | 8302篇 |
2020年 | 9610篇 |
2019年 | 7737篇 |
2018年 | 16492篇 |
2017年 | 14358篇 |
2016年 | 17130篇 |
2015年 | 16843篇 |
2014年 | 25947篇 |
2013年 | 32512篇 |
2012年 | 29858篇 |
2011年 | 32962篇 |
2010年 | 25619篇 |
2009年 | 26347篇 |
2008年 | 31575篇 |
2007年 | 32278篇 |
2006年 | 33611篇 |
2005年 | 30201篇 |
2004年 | 28801篇 |
2003年 | 27214篇 |
2002年 | 26636篇 |
2001年 | 33051篇 |
2000年 | 34523篇 |
1999年 | 26864篇 |
1998年 | 10761篇 |
1997年 | 9309篇 |
1996年 | 8873篇 |
1995年 | 8221篇 |
1994年 | 6569篇 |
1993年 | 6107篇 |
1992年 | 16674篇 |
1991年 | 17984篇 |
1990年 | 17692篇 |
1989年 | 17584篇 |
1988年 | 15964篇 |
1987年 | 15753篇 |
1986年 | 14699篇 |
1985年 | 14279篇 |
1984年 | 10802篇 |
1983年 | 9254篇 |
1979年 | 9882篇 |
1978年 | 7318篇 |
1977年 | 6164篇 |
1976年 | 6298篇 |
1975年 | 7432篇 |
1974年 | 8140篇 |
1973年 | 7882篇 |
1972年 | 7258篇 |
1971年 | 6889篇 |
1970年 | 6497篇 |
Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.
Aims
Variations of the anatomy of donor hepatic arteries increase the number of arterial anastomoses during liver transplantation and, possibly, the incidence of hepatic artery thrombosis (HAT). In this study, we describe the arterial anatomic variations in liver grafts procured and transplanted by a single center in Greece, the techniques of arterial anastomosis, and their effect on the incidence of early HAT.Materials and Methods
From January 2013 to December 2017, the arterial anatomy of 116 grafts procured for liver transplantation were recorded, as well as the technique of arterial anastomosis and the incidence of early hepatic artery thrombosis (HAT <30 days).Results
A single hepatic artery was recorded in 72.41% of the procured grafts, an aberrant left hepatic artery (accessory or replaced) in 18 grafts (15.52%), and an aberrant right hepatic artery (accessory or replaced) in 17 grafts (14.66%), while other variations were observed in less than 1% of the procured livers. Of the 116 primary liver transplantations, 6 patients (5.17%) developed early HAT <30 days. Two of these patients (1.72%) had 1 anastomosis of the hepatic artery and 4 (3.45%) had 2 anastomoses due to anatomic variations.Conclusions
Anatomic variations of the hepatic artery in liver grafts is a common finding and increase the incidence of early HAT but not to a degree to make these grafts unusable. 相似文献Areas covered: the principal pharmacogenetic and non-genetic differences in the pharmacology of tamoxifen and endoxifen are evaluated. To this end, references from PubMed, Embase or Web of Science, among others, were reviewed As non-genetic factors, important differences and similarities such age, or adherence to tamoxifen therapy are comprehensively illustrated. Additionally, since CYP2D6 genotypes are considered the main limitation of tamoxifen, many studies have investigated the association between the worsened clinical outcomes in patients with non-functional CYP2D6 genotypes. In this review, an overview of the research on this field is presented. Also, a summary describing the literature about individualizing tamoxifen therapy with endoxifen concentrations and its limitations is listed.
Expert opinion: z-endoxifen hydrochloride is only investigated in the metastatic setting, still more research is required before its place in therapeutics is known. Similarly, monitoring tamoxifen efficacy based on endoxifen concentrations might not be overall recommended due to the limited evidence available. 相似文献
Areas covered: This review focuses on current treatments and the future outlook for allergic rhinitis. Pharmacotherapy includes mast cell stabilizers, antihistamines, glucocorticosteroids (GCSs), leukotriene receptor antagonists, and nasal decongestants. Nasal GCSs are currently regarded as the most effective treatment and are considered first-line therapy together with non-sedating antihistamines. The new formulation MP29-02 combines the nasal GCS fluticasone propionate with azelastine in one single spray and has achieved greater improvements than those under monotherapy with modern GCSs or antihistamines. Furthermore, this review discusses allergen immunotherapy alone and in combination with modern monoclonal antibodies.
Expert opinion: Despite the variety of medications for allergic rhinitis, ranging from general symptomatic agents like GCSs or decongestants, to more specific ones like histamine receptor or leukotriene blockers, to causal therapy like immunotherapy, many patients still experience treatment failures or unsatisfactory results. The ultimate goal may be to endotype every downstream pathway separately in order to offer patients individualized, targeted therapy with specific antibodies against the respective pathway. 相似文献